Associated Papers
Low-dose lamotrigine co-administration decreases quetiapine plasma concentrations: Effect of UGT2B7-161C>T polymorphism in Japanese patients with depression.
Suzuki T et al.
International Journal of Clinical Pharmacology and Therapeutics, 2026
Impact of UGT1A4 Polymorphisms on the Posaconazole Serum Trough Concentrations in Patients With Acute Myeloid Leukemia Receiving Delayed-Release Tablets.
Parant F et al.
Therapeutic Drug Monitoring, 2025
Human iPSC-based breast cancer model identifies S100P-dependent cancer stemness induced by BRCA1 mutation.
Liu J et al.
Science Advances, 2025
Donor and recipient genetic variants in drug metabolizing enzymes and transporters affect early tacrolimus pharmacokinetics after liver transplantation.
Ladd AD et al.
Scientific Reports, 2025
UGT polymorphisms and epileptic seizure control in pregnant women treated with Lamotrigine.
Hansen NS et al.
Epilepsy Research, 2025
The Loss-of-Function ATP Binding Cassette Subfamily G Member 2 Polymorphism ABCG2 c.421C>A Reduces Lamotrigine Trough Concentrations in Adults with Epilepsy.
Božina N et al.
European Journal of Drug Metabolism and Pharmacokinetics, 2025
Impact of UGT1A4 and UGT2B7 polymorphisms on lamotrigine plasma concentration in patients with bipolar disorder.
Zhao T et al.
Pharmacogenetics and Genomics, 2024
UGT1A4 Polymorphism is not Associated with a Clinically Relevant Change in Giredestrant Exposure.
Malhi V et al.
Cancer Chemotherapy and Pharmacology, 2024
Influence of UGT2B7, UGT1A4 and ABCG2 Polymorphisms on the Pharmacokinetics and Therapeutic Efficacy of Lamotrigine in Patients with Epilepsy.
Yang J et al.
European Journal of Drug Metabolism and Pharmacokinetics, 2024
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
Breast cancer resistance protein polymorphism ABCG2 c.421C>A (rs2231142) moderates the effect of valproate on lamotrigine trough concentrations in adults with epilepsy.
Šušak Sporiš I et al.
Fundamental & Clinical Pharmacology, 2024
UGT1A4*3 polymorphism influences serum concentration and therapeutic effect of lamotrigine for epilepsy treatment: A meta-analysis.
Jiang Z et al.
Plos One, 2024
Somatic mutations reveal hyperactive Notch signaling and racial disparities in prurigo nodularis.
Rajeh A et al.
Medrxiv : the Preprint Server for Health Sciences, 2023
Bearing variant alleles at uridine glucuronosyltransferase polymorphisms UGT2B7 -161C > T (rs7668258) or UGT1A4*3 c.142 T > G (rs2011425) has no relevant consequences for lamotrigine troughs in adults with epilepsy.
Božina N et al.
European Journal of Clinical Pharmacology, 2023
Pharmacogenetics in the Treatment of Huntington's Disease: Review and Future Perspectives.
García-González X et al.
Journal of Personalized Medicine, 2023
Polymorphisms Affecting the Response to Novel Antiepileptic Drugs.
Urzì Brancati V et al.
International Journal of Molecular Sciences, 2023
Effect of UGT1A4, UGT2B7, UGT2B15, UGT2B17 and ABC1B polymorphisms on lamotrigine metabolism in Danish patients.
Petrenaite V et al.
Epilepsy Research, 2022
Estrogen profile- and pharmacogenetics-based lamotrigine dosing regimen optimization: Recommendations for pregnant women with epilepsy.
Wang ML et al.
Pharmacological Research, 2021
Drug-drug-gene interactions as mediators of adverse drug reactions to diclofenac and statins: a case report and literature review.
Božina N et al.
Arhiv Za Higijenu Rada I Toksikologiju, 2021
Generating a Precision Endoxifen Prediction Algorithm to Advance Personalized Tamoxifen Treatment in Patients with Breast Cancer.
Helland T et al.
Journal of Personalized Medicine, 2021
Metabolism of Long-Acting Rilpivirine After Intramuscular Injection: HIV Prevention Trials Network Study 076 (HPTN 076).
Seneviratne HK et al.
Aids Research and Human Retroviruses, 2021
Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone.
Soria-Chacartegui P et al.
Frontiers in Pharmacology, 2021
Influence of genetic variants and antiepileptic drug co-treatment on lamotrigine plasma concentration in Mexican Mestizo patients with epilepsy.
Ortega-Vázquez A et al.
The Pharmacogenomics Journal, 2020
The association of genetic polymorphisms in CYP1A2, UGT1A4, and ABCB1 with autonomic nervous system dysfunction in schizophrenia patients treated with olanzapine.
Hattori S et al.
Bmc Psychiatry, 2020
Predicting novel genomic regions linked to genetic disorders using GWAS and chromosome conformation data - a case study of schizophrenia.
Buxton DS et al.
Scientific Reports, 2019
Comprehensive analysis of coding variants highlights genetic complexity in developmental and epileptic encephalopathy.
Takata A et al.
Nature Communications, 2019
An optimized prediction framework to assess the functional impact of pharmacogenetic variants.
Zhou Y et al.
The Pharmacogenomics Journal, 2019
Meta-analysis of the Influence of UGT Genetic Polymorphisms on Lamotrigine Concentration.
Kim SC et al.
Basic & Clinical Pharmacology & Toxicology, 2019
Effects of Comedication and Genetic Factors on the Population Pharmacokinetics of Lamotrigine: A Prospective Analysis in Chinese Patients With Epilepsy.
Wang ZZ et al.
Frontiers in Pharmacology, 2019
[Relationship between UGT1A4 142T>G polymorphism and serum concentration of lamotrigine in Chinese epileptic patients: a meta-analysis].
Li Z et al.
Zhonghua Yi Xue Za Zhi, 2018
Clinically Relevant Effect of UGT1A4*3 on Lamotrigine Serum Concentration Is Restricted to Postmenopausal Women-A Study Matching Therapeutic Drug Monitoring and Genotype Data From 534 Patients.
Smith RL et al.
Therapeutic Drug Monitoring, 2018
Interaction between ABCG2 421C>A polymorphism and valproate in their effects on steady-state disposition of lamotrigine in adults with epilepsy.
Klarica Domjanović I et al.
British Journal of Clinical Pharmacology, 2018
Pharmacogenetics of ugt genes in North African populations.
Gaibar M et al.
The Pharmacogenomics Journal, 2018
Comprehensive Pharmacogenomic Study Reveals an Important Role of UGT1A3 in Montelukast Pharmacokinetics.
Hirvensalo P et al.
Clinical Pharmacology and Therapeutics, 2018
The Genetic Polymorphism UGT1A4*3 Is Associated with Low Posaconazole Plasma Concentrations in Hematological Malignancy Patients Receiving the Oral Suspension.
Suh HJ et al.
Antimicrobial Agents and Chemotherapy, 2018
Clinical Pharmacokinetics and the Impact of Genetic Polymorphism on a CYP2C19 Substrate, BMS-823778, in Healthy Subjects.
Gong J et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2018
UGT polymorphisms and lamotrigine clearance during pregnancy.
Petrenaite V et al.
Epilepsy Research, 2018
Effects of UGT1A9 genetic polymorphisms on monohydroxylated derivative of oxcarbazepine concentrations and oxcarbazepine monotherapeutic efficacy in Chinese patients with epilepsy.
Lu Y et al.
European Journal of Clinical Pharmacology, 2017
No association between non-bullous skin reactions from lamotrigine and heterozygosity of UGT1A4 genetic variants *2(P24T) or *3(L48V) in Norwegian patients.
Shirzadi M et al.
Seizure, 2017
Pharmacogenetic Variation in Over 100 Genes in Patients Receiving Acenocumarol.
Gonzalez-Covarrubias V et al.
Frontiers in Pharmacology, 2017
Association of UGT2B7 and UGT1A4 Polymorphisms with Serum Concentration of Antiepileptic Drugs in Children.
Du Z et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research, 2016
Pharmacogenetics of UGT1A4, UGT2B7 and UGT2B15 and Their Influence on Tamoxifen Disposition in Asian Breast Cancer Patients.
Sutiman N et al.
Clinical Pharmacokinetics, 2016
Pharmacogenetics of CYP2D6 and tamoxifen therapy: Light at the end of the tunnel?
Del Re M et al.
Pharmacological Research, 2016
Frequencies of UGT1A4*2 (P24T) and *3 (L48V) and their effects on serum concentrations of lamotrigine.
Reimers A et al.
European Journal of Drug Metabolism and Pharmacokinetics, 2016
Influence of valproic acid concentration and polymorphism of UGT1A4*3, UGT2B7 -161C > T and UGT2B7*2 on serum concentration of lamotrigine in Chinese epileptic children.
Liu L et al.
European Journal of Clinical Pharmacology, 2015
The Polymorphic Variant P24T of UDP-Glucuronosyltransferase 1A4 and Its Unusual Consequences.
Troberg J et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2015
Rash and multiorgan dysfunction following lamotrigine: could genetic be involved?
Provenzani A et al.
International Journal of Clinical Pharmacy, 2015
Effects of UGT1A4 genetic polymorphisms on serum lamotrigine concentrations in Chinese children with epilepsy.
Wang Q et al.
Drug Metabolism and Pharmacokinetics, 2015